Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparison of Outcomes Between Low Dose Emicizumab and Extended Half-life Factor VIII With Pharmacokinetic-guided Prophylaxis in Clinically Severe Hemophilia A

Next Previous
Search
Trial Profile

Comparison of Outcomes Between Low Dose Emicizumab and Extended Half-life Factor VIII With Pharmacokinetic-guided Prophylaxis in Clinically Severe Hemophilia A

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 17 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emicizumab (Primary)
  • Indications Haemophilia A
  • Focus Therapeutic Use

Most Recent Events

  • 01 Jan 2025 Results assessing low-dose emicizumab versus low-/intermediate-dose factor VIII for prevention of bleeding, joint health and QoL in patients with noninhibitor severe HA or moderate HA with severe bleeding phenotype, published in the Haemophilia.
  • 04 Mar 2024 Planned primary completion date changed from 21 Feb 2024 to 21 Mar 2024.
  • 07 Dec 2023 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top